DWC202003

Daewoong Pharmaceutical Co. LTD. · Phase 1 active Small molecule

At a glance

Generic name	DWC202003
Sponsor	Daewoong Pharmaceutical Co. LTD.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Pharmacokinetics of DWJ1439, DWJ1464, DWC202003 or DWC202004 in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DWC202003 CI brief — competitive landscape report
DWC202003 updates RSS · CI watch RSS
Daewoong Pharmaceutical Co. LTD. portfolio CI